ES2932278T3 - Composiciones y métodos para prevenir la agregación del vector AAV - Google Patents

Composiciones y métodos para prevenir la agregación del vector AAV Download PDF

Info

Publication number
ES2932278T3
ES2932278T3 ES17186206T ES17186206T ES2932278T3 ES 2932278 T3 ES2932278 T3 ES 2932278T3 ES 17186206 T ES17186206 T ES 17186206T ES 17186206 T ES17186206 T ES 17186206T ES 2932278 T3 ES2932278 T3 ES 2932278T3
Authority
ES
Spain
Prior art keywords
aav
aggregation
vector
virions
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES17186206T
Other languages
English (en)
Spanish (es)
Inventor
John Fraser Wright
Guang Qu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2932278(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ES2932278T3 publication Critical patent/ES2932278T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
ES17186206T 2004-06-01 2005-06-01 Composiciones y métodos para prevenir la agregación del vector AAV Expired - Lifetime ES2932278T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
ES2932278T3 true ES2932278T3 (es) 2023-01-17

Family

ID=35462907

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17186206T Expired - Lifetime ES2932278T3 (es) 2004-06-01 2005-06-01 Composiciones y métodos para prevenir la agregación del vector AAV
ES05755269.7T Expired - Lifetime ES2647477T3 (es) 2004-06-01 2005-06-01 Composiciones y métodos para prevenir la agregación del vector AAV

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05755269.7T Expired - Lifetime ES2647477T3 (es) 2004-06-01 2005-06-01 Composiciones y métodos para prevenir la agregación del vector AAV

Country Status (10)

Country Link
US (4) US7704721B2 (enExample)
EP (3) EP4170024A1 (enExample)
JP (5) JP2008501339A (enExample)
BR (1) BRPI0511764B8 (enExample)
CA (1) CA2569244C (enExample)
DK (2) DK3290513T3 (enExample)
ES (2) ES2932278T3 (enExample)
HU (2) HUE035418T2 (enExample)
MX (3) MX360727B (enExample)
WO (1) WO2005118792A1 (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
PT2529020T (pt) 2010-01-28 2018-07-30 Childrens Hospital Philadelphia Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9879229B2 (en) * 2011-03-14 2018-01-30 National Research Council Of Canada Method of viral production in cells
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
ES2717876T3 (es) * 2011-12-12 2019-06-26 Childrens Hospital Philadelphia Sistema de producción de un vector lentiviral a gran escala comercial y vectores así producidos
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
BR112015031541A2 (pt) 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
US10161011B2 (en) 2013-11-29 2018-12-25 Takara Bio Inc. Method for quantifying adeno-associated virus
DK3546585T3 (da) 2014-04-25 2025-11-03 Genethon Nukleinsyrer med en modificeret intron til brug i behandlingen af hyperbilirubinæmi
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US10526583B2 (en) 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016114992A2 (en) 2015-01-13 2016-07-21 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
KR102877920B1 (ko) 2015-11-16 2025-10-30 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
ES2934848T3 (es) * 2015-12-11 2023-02-27 Univ Pennsylvania Método de purificación escalable para AAV8
WO2017172772A1 (en) * 2016-03-28 2017-10-05 Dimension Therapeutics Methods of heat inactivation of adenovirus
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
AU2017268382B2 (en) 2016-05-18 2023-09-28 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
DK3488007T3 (da) * 2016-07-21 2024-02-19 Spark Therapeutics Inc Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
MX2019002842A (es) 2016-09-12 2019-08-29 Genethon Variantes de alfa-glucosidasa acida y usos de las mismas.
WO2018050872A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
JP7545210B2 (ja) * 2016-11-04 2024-09-04 武田薬品工業株式会社 アデノ随伴ウイルス製剤
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
WO2018141865A1 (en) 2017-02-01 2018-08-09 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
EP3592848A1 (en) 2017-03-10 2020-01-15 Genethon Treatment of glycogen storage disease iii
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
CN120505370A (zh) * 2017-11-08 2025-08-19 诺华股份有限公司 制备病毒载体的手段和方法及其用途
CA3084802A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
SG11202006722RA (en) 2018-01-31 2020-08-28 Res Inst Nationwide Childrens Hospital Gene therapy for limb-girdle muscular dystrophy type 2c
CN120665951A (zh) 2018-02-07 2025-09-19 吉尼松公司 杂合调控元件
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US12129476B2 (en) 2018-04-27 2024-10-29 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
MX2020012077A (es) 2018-05-15 2021-03-09 Voyager Therapeutics Inc Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
EP3801638A1 (en) 2018-06-08 2021-04-14 Novartis AG Cell-based assay for measuring drug product potency
KR20210028162A (ko) 2018-06-29 2021-03-11 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법
AU2019296451B2 (en) * 2018-06-29 2021-04-29 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
AU2019299861A1 (en) 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
MX2020013953A (es) * 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
KR20210043580A (ko) * 2018-08-10 2021-04-21 리젠엑스바이오 인크. 재조합 aav 생산을 위한 규모 조정 가능한 방법
SG11202101032VA (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
EP3861113A1 (en) 2018-10-04 2021-08-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
CN113631225A (zh) 2019-01-18 2021-11-09 沃雅戈治疗公司 用于生产aav颗粒的方法和系统
CA3131390A1 (en) 2019-02-26 2020-09-03 Research Institute Of Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
CN113747926A (zh) 2019-04-08 2021-12-03 吉尼松公司 用于肌肉表达的杂合启动子
JP7630443B2 (ja) 2019-04-19 2025-02-17 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
KR20210153069A (ko) 2019-04-19 2021-12-16 제네똥 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP4004213A1 (en) 2019-07-25 2022-06-01 Novartis AG Regulatable expression systems
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11155835B2 (en) * 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
HRP20240505T1 (hr) 2019-08-21 2024-07-05 Research Institute At Nationwide Children's Hospital Dostava alfa-sarkoglikana vektorom povezanim s adenovirusom i liječenje mišićne distrofije
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN114728049A (zh) 2019-10-07 2022-07-08 再生生物股份有限公司 腺相关病毒载体药物组合物和方法
WO2021078833A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric polypeptides and uses thereof
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
EP4157301A4 (en) * 2020-06-02 2025-03-19 Janssen Biotech, Inc. Materials and methods for viral purification
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
CN116323925A (zh) * 2020-08-07 2023-06-23 詹森生物科技公司 高度纯化的病毒颗粒的制剂
US20230313152A1 (en) 2020-08-24 2023-10-05 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
WO2022094461A1 (en) 2020-11-02 2022-05-05 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
EP4259790A1 (en) 2020-12-09 2023-10-18 Genethon Lysosomal acid lipase variants and uses thereof
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4333896A4 (en) * 2021-05-07 2025-03-19 Board of Regents, The University of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vectors and other molecules
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
CN117980484A (zh) 2021-09-16 2024-05-03 诺华股份有限公司 新颖的转录因子
EP4219726A1 (en) 2021-10-15 2023-08-02 Research Institute at Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
WO2023073526A1 (en) 2021-10-25 2023-05-04 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
WO2023175584A1 (en) 2022-03-17 2023-09-21 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
WO2023175585A1 (en) 2022-03-17 2023-09-21 Innoskel Hybrid promoters and their use in osteolysis syndrome
US20250353883A1 (en) 2022-05-06 2025-11-20 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
CN119343446A (zh) 2022-06-09 2025-01-21 吉尼松公司 用于治疗糖原贮积病iii的n-端截短gde
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
WO2025003477A1 (en) 2023-06-29 2025-01-02 Genethon N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU732703B2 (en) * 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
WO2003097797A2 (en) * 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification

Also Published As

Publication number Publication date
EP3290513A1 (en) 2018-03-07
EP3290513B1 (en) 2022-09-07
JP2019058177A (ja) 2019-04-18
DK1751275T3 (da) 2017-11-27
EP1751275A1 (en) 2007-02-14
JP2014111625A (ja) 2014-06-19
CA2569244C (en) 2017-02-14
JP2008501339A (ja) 2008-01-24
EP4170024A1 (en) 2023-04-26
BRPI0511764B8 (pt) 2021-05-25
JP2012143233A (ja) 2012-08-02
EP1751275B1 (en) 2017-08-16
US20110076744A1 (en) 2011-03-31
US9051542B2 (en) 2015-06-09
US20160083694A1 (en) 2016-03-24
DK3290513T3 (da) 2022-12-12
US20170247664A1 (en) 2017-08-31
HUE060433T2 (hu) 2023-03-28
MXPA06014030A (es) 2007-10-08
MX2019006353A (es) 2022-06-27
JP2016195587A (ja) 2016-11-24
BRPI0511764A (pt) 2008-01-08
JP5769650B2 (ja) 2015-08-26
BRPI0511764B1 (pt) 2017-10-24
CA2569244A1 (en) 2005-12-15
EP1751275A4 (en) 2008-01-23
US7704721B2 (en) 2010-04-27
MX360727B (es) 2018-11-14
US20060035364A1 (en) 2006-02-16
ES2647477T3 (es) 2017-12-21
WO2005118792A1 (en) 2005-12-15
HUE035418T2 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
ES2932278T3 (es) Composiciones y métodos para prevenir la agregación del vector AAV
ES2862206T3 (es) Viriones de AAV con inmunorreactividad disminuida y sus usos
Hauswirth et al. [48] Production and purification of recombinant adeno-associated virus
ES2711349T3 (es) Cápside
US10294452B2 (en) Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
Lagor et al. Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism
Huszthy et al. Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts
de Silva et al. Adeno-associated viral gene therapy for retinal disorders
CN101018858A (zh) 防止aav载体聚集的组合物和方法
US20210123028A1 (en) Formulation optimization for viral particles
HK40091911A (en) Compositions and methods to prevent aav vector aggregation
ES2969222T3 (es) Métodos y composiciones para el tratamiento de enfermedades del almacenamiento de glucógeno
JP2024515902A (ja) 組織向性が改善されたアデノ随伴ウイルスベクターカプシド
TW202426017A (zh) 非包膜病毒的藥物組合物
US10961512B2 (en) Compositions and kits for purification of viral particles from host cells
JP2025522870A (ja) アルツハイマー病の治療及び予防のための方法及び医薬組成物
Song et al. AAV vector mobilization, risk vs reality